Strategy and tactics of treatment in patients with metastatic colorectal cancer
https://doi.org/10.18027/2224-5057-2015-2-78-84
Abstract
Colorectal cancer is one of the most frequently detected malignancies worldwide. Incidence and mortality rates continue to grow steadily that is due, on the one hand, to the late disease diagnostics, and on the other hand – to the high distant metastases rate. More than a half of all metastatic colorectal cancer patients reveal distant liver metastases. The isolated liver lesions can be the only systemic disease manifestation when early cytoreduction allows the achievement of a significant increase in life expectancy, and in some cases – the complete recovery of such patients. However, so far there was no uniform treatment strategy of patients with colorectal cancer with liver metastases due to the heterogeneity of patients and the difficulties of selecting the treatment volume. The world’s leading experts have made an attempt to identify a number of prognostic factors for the selection of patients who have been considered suitable for an intensive treatment due to their metastatic disease. It is generally recognized that the conduction of combined treatment in these patients significantly improves survival but the choice of specific treatment and the timing of its application is still a subject of debates among experts. The authors present their own data concerning the methods and the results of metastatic colorectal cancer patients’ treatment.
About the Authors
A. B. Moiseenko
Federal State Budget institution N. N. Petrov scientific research institute
Russian Federation
к. м.н., хирург-онколог отделения абдоминальной онкологии, St.Petersburg
Russian Federation
к. м.н., хирург-онколог отделения абдоминальной онкологии, St.Petersburg
ALEKSEY GULYAEV
ФГБУ НИИ онкологии им. Н. Н. Петрова
Russian Federation
д. м.н., профессор, руководитель отделения абдоминальной онкологии, Санкт-Петербург
Russian Federation
д. м.н., профессор, руководитель отделения абдоминальной онкологии, Санкт-Петербург
ALEKSEY KARACHUN
ФГБУ НИИ онкологии им. Н. Н. Петрова
Russian Federation
д. м.н., заведующий отделением абдоминальной онкологии, Санкт-Петербург
Russian Federation
д. м.н., заведующий отделением абдоминальной онкологии, Санкт-Петербург
ANNA BELYAEVA
ФГБУ НИИ онкологии им. Н. Н. Петрова
Russian Federation
к. м.н., научный сотрудник отделения абдоминальной онкологии, Санкт-Петербург
Russian Federation
к. м.н., научный сотрудник отделения абдоминальной онкологии, Санкт-Петербург
ALEXANDER KORNILOV
ФГБУ НИИ онкологии им. Н. Н. Петрова
Russian Federation
к. м.н., хирург-онколог отделения абдоминальной онкологии, Санкт-Петербург
Russian Federation
к. м.н., хирург-онколог отделения абдоминальной онкологии, Санкт-Петербург
References
1. Aliev V.A., Barsukov Yu.A., Nikolaev A.V. et al. Justification of providing operations for cytoruduction for metastatic colorectal cancer – a surgeon’s opinion. Malignant tumors. 2012. Vol.2. № 2 – p. 40–45.
2. Chissov V.I., Starinskiy V.V., Petrova G.V. Malignant tumors in Russia in 2007 (morbidity and mortality). Moscow. 2009. p.252.
3. Merabishvili V.M. Malignant tumors in the world, in Russia and in St.Petersburg. 2007/ – p/422.
4. Merabishvili V.M. Oncological service in St/Petersburg in 2007 (morbidity, mortality, survival). St.Petersburg. 2008. p.256.
5. Treatment of malignant tumors Oncologists And Chemotherapeutists Society guideline. 2013.
6. Patyutko Yu.I., Sagaydak I.V., Polyakov A.V. Combined treatment of patients with colorectal cancer with metastatic lesions of the liver. Russian medical journal/ 2009/ Vol.13. p.853–862.
7. Kaprin A.D., Starinskiy V.V., Petrova G.V. Current status of oncological service in Russia in 2013. Moscow. 2014. p.235.
8. Adam R., Aloia T. A. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement?// J ClinOncol, 2009.– Vol. 27.– P. 1343–1345.
9. Adam R., Wicherts D. A., De Haas R. J. et al. Complete pathologic response af ter preoperative chemotherapy for colorectal liver metastases: myth or reality?// Journal of Clinical Oncology, 2008.– Vol. 26, No. 10.– P. 1635–1641.
10. AJCC Cancer Staging Handbook. Seventh Edition. – 2010. SpringerScience+Business Media LLC. – 718 p.
11. Allen P. J., Kemeny N., Jarnagin W.et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases.// Journal of Gastrointestinal Surgery, 2003.– Vol. 7, No. 1. – P. 109–115.
12. Benoist S., Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases.//Annals of Surgical Oncology, 2009.– Vol. 16, No. 9.– P. 2385–2390.
13. Blazer D. G. III, Kishi Y., Maru D. M.et al. Pathologic response to preoperative chemotherapy: a new outcome end point af ter resection of hepatic colorectal metastases.// Journal of Clinical Oncology, 2008.– Vol. 26, No. 33.– P. 5344–5351.
14. Cancer incidence in five continents. V ol. IX./ Ed. by M. P. Curado et al.– IARC. – 2007.– P.896.
15. Chen J., Li Q., Wang C. et al. Simultaneous vs. staged resection for synchronous colorectal liver metastases: a metaanalysis,// International Journal of Colorectal Disease, 2011.– Vol. 26, No. 2 – P. 191–199.
16. Haddad A. J., Bani Hani M., Pawlik T. M., Cunningham S. C. Colorectal Liver Metastases.// International Journal of Surgical Oncology, 2011.– Vol.2011. – P.286840.
17. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin. – 2010. – V.60 – № 5.– P.277–300.
18. Khan K., Wale A., Brown G., Chau I. Colorectal cancer with liver metastases: Neoadjuvant chemotherapy, surgical resection first or palliation alone?//World J Gastroenterol, 2014.– Vol. 20., I.35 – P. 12391–12406.
19. McCarter, M.D. and Y. Fong. Role for surgical cytoreduction in multimodality treatments for cancer // Ann. Surg. Oncol. – 2001.– Vol.8, I.1.– P.38–43.
20. National Comprehensive Cancer Network, version 1.2015.
21. Nordlinger B., Sorbye H., GlimeliusB. et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.//The Lancet, 2008.– Vol. 371, No. 9617. – P. 1007–1016.
22. Reddy S. K., Barbas A. S., Clary B. M. Synchronous colorectal liver metastases: is it time to reconsider traditional paradigms of management?// Annals of Surgical Oncology, 2009.– Vol. 16, No. 9, pp. 2395–2410.
23. Rosen S. A. et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be? // Arch. Surg. – 2000.– Vol.135 (5).– P.530–535.
24. Schindl M., Wigmore S. J., Currie E. J. et al. Prognostic scoring in colorectal cancer liver metastases: development and validation.//Archives of Surgery, 2005.– Vol. 140, No. 2.– P. 183–189.
25.
Review
For citations:
Moiseenko A.B., GULYAEV A., KARACHUN A., BELYAEVA A., KORNILOV A. Strategy and tactics of treatment in patients with metastatic colorectal cancer. Malignant tumours. 2015;(2):78-84. (In Russ.) https://doi.org/10.18027/2224-5057-2015-2-78-84
Views:
1880
Email this article 